AXCELIS TECHNOLOGIES INC
At today's price, AXCELIS TECHNOLOGIES INC (ACLS) is priced for today's economics sustained for ~20.0 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Axcelis sells ion implantation systems, a critical step in making chips, with a franchise concentrated in power and memory devices, and the business is deep in the cyclical part of its cycle: trailing revenue has been falling and the operating margin sits near 11.6%, well below the peak the equipment makers earn at the top. • The defining risk is geographic and political: customers in Asia took 76.0% of system revenue in 2025, and the filing warns that U.S. export controls raise the chance Chi
Is ACLS overvalued? See what's priced in →
363 institutional managers reported holding ACLS in 13F filings for the quarter ended 2026-03-31. 59 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 1.9M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ACLS has cut its share count 8.8% over the past five years, spending $316.56M on repurchases. It pays no dividend. Cash returned over the past three years: $209.07M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ACLS over the trailing three years: 2024: 3 buys totaling $116k. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ACLS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-02-26 | +8.8% | -21.6% |
| 2022-05-06 | +0.3% | -10.2% |
| 2022-08-05 | +12.2% | -21.4% |
| 2022-11-04 | +1.8% | +34.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ACLS's latest 8-K filings: 2026-05-07 (items 2.02, 9.01); 2026-05-06 (items 5.07); 2026-03-12 (items 5.02, 7.01, 9.01); 2026-02-17 (items 2.02, 9.01); 2026-02-06 (items 5.07, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.